Bristol Myers beat Q2 revenue and EPS estimates; raised full-year revenue guidance to $49–$50 billion and EPS guidance to $6.75–$7, and raised Eliquis revenue growth outlook to 20–25%.
FirstSquawk07/30, 06:04 PM
- Q2 REV $12.97 BLN
- IBES ESTIMATE $11.75 BLN
- OUTLOOK FY REV ABOUT $49 BLN TO $50 BLN
- IBES ESTIMATE $47.47 BLN
Figures as quoted by FirstSquawk
Related assets
Coming up for BMY
Explore next
Latest BMY news
Jin1008/05, 07:04 PM
Astrazeneca and Bristol Myers Squibb have no ongoing discussions regarding a potential transaction.
Finnhub08/04, 12:17 AM
Finnhub08/03, 10:50 PM